As of 11:05 EST Monday morning, shares of Nanobiotix, a clinical-stage biotechnology firm, had witnessed five consecutive sessions of gains, which resulted in its share price rising 12.07% to EUR8.45. This outperformed the CAC 40 index which saw its value fall 0.19% over that same time frame. This could suggest there has been some weakness during Monday trading session or could indicate potential weakness further ahead.
Nanobiotix’s Share Price Performance
Nanobiotix closed its previous trading day at EUR7.54, just missing their 52-week high of EUR7.60 by 0.79%. Their primary aim is to develop solutions for cancer and other unmet medical needs; their flagship product candidate NBTXR3 being their prime example.
Comparison to Moving Averages
Nanobiotix’s worth has significantly outshone both its 50-day moving average of EUR5.01 and 200-day moving average of EUR3.95 since March 2017, signaling a promising trend for shareholders. Unfortunately, though, its trailing twelve-month earnings per share (EPS) figure of EUR-1.74 indicates a lack of profitability during this time.
Trading Volume & Investor Enthusiasm
Nanobiotix reported an impressive last-day trading volume of 736,556, an increase of 92.87% from its average volume of 381,882. This activity may indicate increased investor enthusiasm about Nanobiotix shares as evidenced by their recent performance.
Future Prospects & Partnerships
As Nanobiotix joins forces with Lian Oncology Limited to introduce NBTXR3 across markets including Greater China, South Korea, Singapore and Thailand, its share performance will likely depend heavily on this lead product candidate’s successful commercialization and advancement.
More news about NANOBIOTIX (NANO.PA).
